Atezolizumab for adjuvant treatment of high-risk locally advanced squamous cell head and neck cancer [ID4052]
Discontinued
Reference number: GID-TA10933
Following the changes to remove technical engagement as standard from appraisal timelines, the timelines for the appraisal of Atezolizumab for adjuvant treatment of high-risk locally advanced squamous cell head and neck cancer have been revised. It is anticipated that the appraisal will begin in early-March 2024 when we will write to you about how you can get involved.